Company news
Cingulate Inc. news in 2025
Cingulate Inc.'s news releases, calls and decks from 2025, newest first.
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
November 10, 2025
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
October 28, 2025
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
October 23, 2025
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
October 14, 2025
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
September 17, 2025
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
August 19, 2025
Cingulate Provides Management Team Update
August 15, 2025
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
August 6, 2025
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
July 29, 2025
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
July 9, 2025
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 20, 2025
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
May 14, 2025
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
May 8, 2025
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
April 29, 2025
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
April 9, 2025
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
April 3, 2025
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
March 26, 2025
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
March 4, 2025
Decks in 2025
- Technical Presentation (2025)
Technical · 10 slides · 2025